Publicacións en colaboración con investigadores/as de Universitat Autònoma de Barcelona (59)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

  2. Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO)

    Thrombosis Update, Vol. 17

  3. Exercise in cancer patients: assistance levels and referral pathways—a position statement from the Spanish Society of Medical Oncology

    Clinical and Translational Oncology

  4. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  5. Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 98-108

  6. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

    European urology oncology, Vol. 7, Núm. 3, pp. 447-455

  7. Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer: towards the clinical application

    Journal of Experimental and Clinical Cancer Research, Vol. 43, Núm. 1

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

  2. Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2679-2691), 10.1007/s12094-023-03216-3)

    Clinical and Translational Oncology

  3. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 796-802

  4. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

  5. Noninvasive detection of microsatellite instability in patients with endometrial cancer

    International Journal of Cancer, Vol. 152, Núm. 10, pp. 2206-2217

  6. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

  7. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

    Therapeutic Advances in Medical Oncology, Vol. 15

  8. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2679-2691

2022

  1. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115

  2. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

  3. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

    British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880

  4. Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

    Oncogene, Vol. 41, Núm. 13, pp. 1835-1850

  5. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 1209-1214